Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Company Info
Contact US
Moleculin Biotech, Inc.
Drug Discovery & Development
Overview
Contact US
Contributions
Contributors
Contributions
2 Contributions
1 / 1
1 / 1
0 Contributors
1 / 0
1 / 0
No authors found
AML
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
Moleculin Biotech, Inc.
PR-11-24-NI-102
Nov 15, 2024
Clinical Trials
Moleculin Receives Institutional Review Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin for the Treatment
Moleculin Biotech, Inc.
PR-10-24-NI-93
Nov 12, 2024
